260 related articles for article (PubMed ID: 23530878)
21. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
22. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
23. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
[TBL] [Abstract][Full Text] [Related]
24. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
Wiseman GA; Leigh BR; Dunn WL; Stabin MG; White CA
Cancer Biother Radiopharm; 2003 Apr; 18(2):253-8. PubMed ID: 12804052
[TBL] [Abstract][Full Text] [Related]
25. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
Vanazzi A; Grana C; Crosta C; Pruneri G; Rizzo S; Radice D; Pinto A; Calabrese L; Paganelli G; Martinelli G
Hematol Oncol; 2014 Mar; 32(1):10-5. PubMed ID: 23696416
[TBL] [Abstract][Full Text] [Related]
27. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
28. Radioisotopic localization of (90)Yttrium-ibritumomab tiuxetan in patients with CD20+ non-Hodgkin's lymphoma.
Jacobs SA; Harrison AM; Swerdlow SH; Foon KA; Avril N; Vidnovic N; Joyce J; DeMonaco N; McCarty KS
Mol Imaging Biol; 2009; 11(1):39-45. PubMed ID: 18773247
[TBL] [Abstract][Full Text] [Related]
29. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
[TBL] [Abstract][Full Text] [Related]
30. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
Emmanouilides C; Witzig TE; Gordon LI; Vo K; Wiseman GA; Flinn IW; Darif M; Schilder RJ; Molina A
Leuk Lymphoma; 2006 Apr; 47(4):629-36. PubMed ID: 16690521
[TBL] [Abstract][Full Text] [Related]
31. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.
Hoffmann M; Troch M; Eidherr H; Traub-Weidinger T; Jonak C; Muellauer L; Raderer M
Leuk Lymphoma; 2011 Jan; 52(1):42-5. PubMed ID: 21133720
[TBL] [Abstract][Full Text] [Related]
32. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
[TBL] [Abstract][Full Text] [Related]
34. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Micallef IN
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM
Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981
[TBL] [Abstract][Full Text] [Related]
36. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
Grillo-López AJ
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025
[TBL] [Abstract][Full Text] [Related]
37. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
Gregory SA
Semin Oncol; 2003 Dec; 30(6 Suppl 17):17-22. PubMed ID: 14710399
[TBL] [Abstract][Full Text] [Related]
38. Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma.
Koechli V; Klaeser B; Banz Y; Mueller BU; Pabst T
Leuk Res; 2015 Mar; 39(3):307-10. PubMed ID: 25616614
[TBL] [Abstract][Full Text] [Related]
39. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Johnston PB; Bondly C; Micallef IN
Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
[TBL] [Abstract][Full Text] [Related]
40. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
